Articles from THL Partners

THL Partners, a premier private equity firm investing in middle-market growth companies, today announced the final close of THL Equity Fund X, L.P. (“Fund X”) with $6.35 billion in investable capital.

Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies. The investment will support Celerion’s continued growth and innovation, including expanding its clinical and bioanalytical capabilities and advancing its work to help pharmaceutical and biotechnology partners bring new therapies to patients worldwide.

THL Partners (“THL”), a premier private equity firm investing in middle market growth companies, today announced the entry into a definitive agreement to acquire Headlands Research (“Headlands” or “the Company”), a leading multinational network of clinical trial sites, from funds managed by leading global investment firm KKR. The strategic partnership between THL and Headlands will fuel Headlands’ continued expansion, enhance its technology and centralized infrastructure, and further strengthen its ability to deliver high-quality, diverse clinical trial data for pharmaceutical and biotech sponsors in support of Headlands’ mission to improve lives by advancing innovative medical therapies.